Kura Oncology to Report Second Quarter 2016 Financial Results

Management to host webcast and conference call on August 10, 2016 at 1:15 p.m. PDT/4:15 p.m. EDT

San Diego, California, UNITED STATES

LA JOLLA, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced it will report second quarter 2016 financial results after the close of U.S. financial markets on August 10, 2016. Management will host a webcast and conference call at 1:15 p.m. PDT/4:15 p.m. EDT that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-516-3514 for domestic callers and 281-973-6129 for international callers and entering the conference code: 60855133. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 60855133.
About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.  Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is being studied in multiple Phase 2 clinical trials. The preclinical pipeline includes KO-947, an ERK inhibitor, as well as an inhibitor of the menin-MLL interaction. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.


Contact Data